Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 8;16(1):2347715. doi: 10.1080/19490976.2024.2347715

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Société des Produits Nestlé SA. Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 5. — Overview of changes in plasma butyric acid and associations with clinical endpoints and fecal BL NCC3001 counts.

A) Concentrations of butyric acid in plasma at baseline (V1) and end of intervention (V2) per group, B) Correlation between the difference in HADA score (V2-V1) and butyric acid concentration in plasma at V2; Spearman test, C) Correlation between the difference in HADD score (V2-V1) and butyric acid concentration in plasma at V2; Spearman test. D) Correlation between amygdala activation (fMRi) and butyric acid concentration in the plasma at V2; Spearman test. E) Correlation between fecal BL NCC3001 abundance and butyric acid concentration in plasma at V2; Spearman test. BL NCC3001 (BL, open circle); Placebo (P, closed circle).